Treatment of spinal muscular atrophy by sodium butyrate

Citation
Jg. Chang et al., Treatment of spinal muscular atrophy by sodium butyrate, P NAS US, 98(17), 2001, pp. 9808-9813
Citations number
38
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
ISSN journal
00278424 → ACNP
Volume
98
Issue
17
Year of publication
2001
Pages
9808 - 9813
Database
ISI
SICI code
0027-8424(20010814)98:17<9808:TOSMAB>2.0.ZU;2-T
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive disease characteriz ed by degeneration of the anterior horn cells of the spinal cord, leading t o muscular paralysis with muscular atrophy. No effective treatment of this disorder is presently available. Studies of the correlation between disease severity and the amount of survival motor neuron (SMN) protein have shown an inverse relationship. We report that sodium butyrate effectively increas es the amount of exon 7-containing SMN protein in SMA lymphoid cell lines b y changing the alternative splicing pattern of exon 7 in the SMN2 gene. In vivo, sodium butyrate treatment of SMA-like mice resulted in increased expr ession of SMN protein in motor neurons of the spinal cord and resulted in s ignificant improvement of SMA clinical symptoms. Oral administration of sod ium butyrate to intercrosses of heterozygous pregnant knockout-transgenic S MA-like mice decreased the birth rate of severe types of SMA-like mice, and SMA symptoms were ameliorated for all three types of SMA-like mice. These results suggest that sodium butyrate may be an effective drug for the treat ment of human SMA patients.